Profile data is unavailable for this security.
About the company
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
- Revenue in USD (TTM)37.16m
- Net income in USD-25.53m
- Incorporated2014
- Employees186.00
- LocationCytosorbents Corp305 COLLEGE ROAD EASTPRINCETON 08540United StatesUSA
- Phone+1 (973) 329-8885
- Websitehttps://cytosorbents.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexalin Technology Inc | 150.16k | -5.40m | 42.96m | 6.00 | -- | 18.76 | -- | 286.08 | -0.7261 | -0.7261 | 0.0202 | 0.1781 | 0.0446 | 0.1679 | 11.53 | 25,026.67 | -160.37 | -- | -202.23 | -- | 82.94 | -- | -3,598.50 | -- | 4.89 | -- | 0.00 | -- | -91.62 | -- | -173.80 | -- | -- | -- |
| Vivos Inc | 25.00k | -2.81m | 44.60m | 10.00 | -- | 27.87 | -- | 1,783.83 | -0.0075 | -0.0075 | 0.00007 | 0.0038 | 0.014 | -- | 2.56 | -- | -157.67 | -202.25 | -171.09 | -552.77 | -3.12 | 10.79 | -11,223.64 | -11,969.07 | -- | -- | 0.00 | -- | -46.58 | -- | -17.19 | -- | -- | -- |
| Outset Medical Inc | 114.73m | -140.94m | 44.83m | 480.00 | -- | 0.9373 | -- | 0.3907 | -2.77 | -2.77 | 2.25 | 0.9102 | 0.3822 | 1.44 | 3.29 | 239,018.80 | -46.94 | -41.40 | -55.82 | -47.29 | 30.97 | 5.71 | -122.84 | -159.05 | 5.04 | -11.24 | 0.8048 | -- | 13.00 | 130.43 | -6.04 | -- | 14.27 | -- |
| Accelerate Diagnostics Inc | 12.23m | -37.91m | 47.83m | 134.00 | -- | -- | -- | 3.91 | -2.07 | -2.07 | 0.6853 | -1.47 | 0.3363 | 2.14 | 5.28 | 91,291.05 | -104.22 | -75.24 | -1,349.93 | -94.46 | 27.16 | 35.08 | -309.87 | -638.55 | 1.04 | -- | 6.38 | -- | -5.43 | 16.29 | 1.40 | -- | 0.7307 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 216.00k | -7.97m | 49.11m | 10.00 | -- | -- | -- | 227.37 | -0.5682 | -0.5682 | 0.0154 | -0.0203 | 0.0575 | -- | -- | 21,600.00 | -212.20 | -330.30 | -448.71 | -1,524.88 | 77.31 | -- | -3,689.35 | -35,138.84 | 0.2992 | -- | 2.38 | -- | -- | -- | -44.28 | -- | -39.07 | -- |
| Cytosorbents Corp | 37.16m | -25.53m | 50.85m | 186.00 | -- | 3.90 | -- | 1.35 | -0.526 | -0.526 | 0.7451 | 0.3082 | 0.702 | 4.14 | 5.01 | 202,900.80 | -48.23 | -36.00 | -59.94 | -43.52 | 64.56 | 68.15 | -68.70 | -62.71 | 1.71 | -17.64 | 0.4496 | -- | 4.79 | 10.06 | 13.12 | -- | -9.24 | -- |
| DIH Holding US Inc | 67.62m | -6.14m | 51.49m | 192.00 | -- | -- | -- | 0.7616 | -0.1903 | -0.1903 | 1.96 | -0.9841 | 1.99 | 4.12 | 11.80 | 352,161.50 | -18.09 | -- | -- | -- | 48.86 | -- | -9.09 | -- | 0.4221 | -3.38 | -- | -- | 19.26 | -- | -732.64 | -- | -- | -- |
| Nutriband Inc | 1.80m | -7.24m | 54.04m | 13.00 | -- | 4.34 | -- | 29.96 | -0.8122 | -0.8122 | 0.1984 | 1.12 | 0.1535 | 6.29 | 12.38 | -- | -61.64 | -55.21 | -67.30 | -66.74 | 33.62 | 33.32 | -401.62 | -315.87 | 6.36 | -- | 0.0156 | -- | 0.2741 | 53.43 | -22.35 | -- | 65.57 | -- |
| Milestone Scientific Inc | 8.42m | -4.62m | 54.10m | 17.00 | -- | 6.79 | -- | 6.42 | -0.0614 | -0.0614 | 0.1096 | 0.103 | 0.7274 | 0.5763 | 14.32 | 495,440.60 | -40.16 | -55.48 | -56.48 | -74.72 | 72.44 | 63.97 | -55.21 | -88.94 | 1.81 | -- | 0.0007 | -- | 11.60 | 0.4233 | 20.41 | -- | -7.99 | -- |
| Rapid Micro Biosystems Inc | 26.17m | -48.40m | 54.65m | 193.00 | -- | 0.646 | -- | 2.09 | -1.11 | -1.11 | 0.6028 | 1.97 | 0.2045 | 1.32 | 6.78 | 135,595.90 | -37.81 | -- | -43.12 | -- | -4.82 | -- | -184.93 | -- | 4.19 | -- | -- | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| iCAD Inc | 18.80m | -4.54m | 56.00m | 67.00 | -- | 1.80 | -- | 2.98 | -0.1735 | -0.088 | 0.7185 | 1.17 | 0.4488 | 1.06 | 3.14 | 280,537.30 | -10.84 | -23.94 | -13.90 | -34.14 | 86.04 | 76.96 | -24.16 | -45.02 | 4.13 | -- | 0.00 | -- | -12.54 | -7.53 | 29.32 | -- | 23.88 | -- |
| Lucid Diagnostics Inc | 3.80m | -54.15m | 56.69m | 70.00 | -- | -- | -- | 14.92 | -1.23 | -1.23 | 0.0857 | 0.3238 | 0.0992 | -- | 38.97 | 54,285.71 | -121.82 | -- | -274.96 | -- | -67.39 | -- | -1,227.76 | -- | 1.71 | -- | 0.4178 | -- | 544.03 | -- | 6.24 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.72m | -91.89m | 57.10m | 255.00 | -- | 0.414 | -- | 20.98 | -37.37 | -37.37 | 1.11 | 55.27 | 0.0108 | 0.2867 | 11.53 | 10,674.51 | -36.46 | -- | -38.85 | -- | -41.11 | -- | -3,375.72 | -- | 8.04 | -- | 0.0696 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Pheton Holdings Ltd | 628.59k | -241.22k | 57.43m | 11.00 | -- | 157.90 | -- | 91.36 | -0.0201 | -0.0201 | 0.0524 | 0.0255 | -- | -- | -- | 57,144.55 | -- | -- | -- | -- | 74.90 | -- | -38.37 | -- | 0.3984 | -- | 0.00 | -- | -7.53 | -- | -387.24 | -- | -- | -- |
| Medinotec Inc | 8.38m | -21.86k | 58.67m | 35.00 | -- | -- | 755.65 | 7.00 | -0.0019 | -0.0019 | 0.7146 | 0.2156 | 1.64 | 5.02 | 17.62 | 239,561.70 | -0.4275 | -- | -0.5122 | -- | 42.89 | -- | -0.2607 | -- | 2.32 | 6.61 | 0.3165 | -- | 402.25 | -- | -14.73 | -- | -- | -- |
| Alpha Pro Tech, Ltd. | 59.29m | 4.14m | 58.73m | 124.00 | 14.57 | 0.9424 | 11.48 | 0.9907 | 0.3664 | 0.3664 | 5.24 | 5.67 | 0.8596 | 1.68 | 9.07 | 478,121.00 | 6.01 | 15.21 | 6.22 | 16.06 | 39.55 | 40.23 | 6.99 | 12.93 | 11.21 | -- | 0.00 | 0.00 | -1.21 | 5.60 | 27.64 | 2.93 | 5.50 | -- |
Data as of Nov 12 2024. Currency figures normalised to Cytosorbents Corp's reporting currency: US Dollar USD
29.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avenir Corp.as of 30 Jun 2024 | 2.97m | 5.46% |
| Skylands Capital LLCas of 30 Sep 2024 | 2.76m | 5.06% |
| Granahan Investment Management, LLCas of 30 Jun 2024 | 2.66m | 4.89% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.94m | 3.56% |
| Sargent Investment Group LLCas of 30 Sep 2024 | 1.63m | 2.99% |
| Neuberger Berman Investment Advisers LLCas of 30 Jun 2024 | 1.54m | 2.82% |
| CM Management LLCas of 30 Jun 2024 | 850.00k | 1.56% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 653.39k | 1.20% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 606.98k | 1.12% |
| Geode Capital Management LLCas of 30 Jun 2024 | 434.64k | 0.80% |
More ▼
Data from 30 Apr 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
